|
|
Post by kite on Nov 1, 2022 7:39:34 GMT -5
|
|
|
|
Post by neil36 on Nov 1, 2022 8:15:55 GMT -5
This is nice to finally see happening. One of my best friends in childhood had epilepsy and I witnessed several of his seizures and some of them were quite severe. I wish this program every success in the world. 3.4 million people in the U.S. with epilepsy. 65 million worldwide. |
|
|
|
Post by caesar on Nov 1, 2022 8:17:07 GMT -5
So once the 30 calendar days pass after filing the IND, Receptor should/will initiate clinical trials. Supposedly, during this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.
Good news & very promising...
|
|
|
|
Post by neil36 on Nov 1, 2022 8:37:44 GMT -5
And of course the $100 million dollar question we've all been asking for what feels like a decade:
When will MNKD see its next milestone payment from RLS???
|
|
|
|
Post by cretin11 on Nov 1, 2022 9:29:55 GMT -5
And of course the $100 million dollar question we've all been asking for what feels like a decade: When will MNKD see its next milestone payment from RLS??? It does feel like a decade. But is it really a $100 million dollar question? In other words, do we know the amount of the next milestone payment, and what exactly triggers it? Apologies for not remembering, I know it’s somewhere on this board but I’m being lazy. |
|
|
|
Post by neil36 on Nov 1, 2022 9:33:35 GMT -5
VALENCIA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeutic products will be developed to explore their potential to treat conditions such as chronic pain, neurologic diseases and inflammatory disorders.
Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.
"We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind. "This collaboration demonstrates the fundamental value of our platform technology while the risk-sharing structure of the transaction allows us to diversify our product opportunities without losing focus on our lead program."
About Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market.
Inquiries: info@receptorlife.com
|
|
|
|
Post by peppy on Nov 1, 2022 9:42:12 GMT -5
VALENCIA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeutic products will be developed to explore their potential to treat conditions such as chronic pain, neurologic diseases and inflammatory disorders. Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product. "We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind. "This collaboration demonstrates the fundamental value of our platform technology while the risk-sharing structure of the transaction allows us to diversify our product opportunities without losing focus on our lead program." About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. Inquiries: info@receptorlife.com Yippee.  |
|
|
|
Post by cretin11 on Nov 1, 2022 9:47:42 GMT -5
“Marijuana Leaf” nice! Maybe they didn’t know in 1949 that the buds work better…
Has it been disclosed how the milestones work for this collab? We know the max aggregate amount, but what would the next milestone payment be and what would trigger it?
|
|
|
|
Post by peppy on Nov 1, 2022 10:06:43 GMT -5
“Marijuana Leaf” nice! Maybe they didn’t know in 1949 that the buds work better… Has it been disclosed how the milestones work for this collab? We know the max aggregate amount, but what would the next milestone payment be and what would trigger it? Hemp or Bud, who cares. Listening to people that make the paste out of hemp, hemp worked. The insert is the medical establishment pharmaceuticals. Seated next to his mother using CBD to control seizures.  |
|
|
|
Post by Thundersnow on Nov 1, 2022 10:38:06 GMT -5
VALENCIA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeutic products will be developed to explore their potential to treat conditions such as chronic pain, neurologic diseases and inflammatory disorders. Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product. "We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind. "This collaboration demonstrates the fundamental value of our platform technology while the risk-sharing structure of the transaction allows us to diversify our product opportunities without losing focus on our lead program." About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. Inquiries: info@receptorlife.com MNKD needs to renegotiate that deal. It's been 6 years and it will take another 3 years before product is sold. |
|
|
|
Post by mango on Nov 1, 2022 10:57:06 GMT -5
I’m going to guess the next milestone payment is contingent on FDA approval or perhaps even a successful Phase 3 clinical trial, but seems unlikely considering the way it’s been unfolding heretofore.
I suspect we will see a major BP partnership announcement from Receptor in the near future.
If Receptor is successful in gaining FDA approval, and ultimately commercialization of their two products utilizing MannKind’s revolutionary Technosphere dry powder drug delivery inhalation platform, MannKind will be receiving two new royalties streams.
😎
|
|
|
|
Post by cretin11 on Nov 1, 2022 11:37:52 GMT -5
I’m going to guess the next milestone payment is contingent on FDA approval or perhaps even a successful Phase 3 clinical trial, but seems unlikely considering the way it’s been unfolding heretofore. I suspect we will see a major BP partnership announcement from Receptor in the near future. If Receptor is successful in gaining FDA approval, and ultimately commercialization of their two products utilizing MannKind’s revolutionary Technosphere dry powder drug delivery inhalation platform, MannKind will be receiving two new royalties streams. 😎 By near future, do you mean within a year, or even more quickly? |
|
|
|
Post by mango on Nov 1, 2022 11:59:37 GMT -5
I’m going to guess the next milestone payment is contingent on FDA approval or perhaps even a successful Phase 3 clinical trial, but seems unlikely considering the way it’s been unfolding heretofore. I suspect we will see a major BP partnership announcement from Receptor in the near future. If Receptor is successful in gaining FDA approval, and ultimately commercialization of their two products utilizing MannKind’s revolutionary Technosphere dry powder drug delivery inhalation platform, MannKind will be receiving two new royalties streams. 😎 By near future, do you mean within a year, or even more quickly? It would make sense for a BP company to wait for Phase 1 results before inking a deal, and was the case with MNKD and UTHR. Unless Receptor’s plan is to go solo, then this is what I suspect will happen. I and no one else can predict the future, cretin. If and when this occurs remains to be seen. |
|
|
|
Post by cretin11 on Nov 1, 2022 12:13:28 GMT -5
Yeah I was curious why you specified “in the near future.”
|
|
|
|
Post by mango on Nov 1, 2022 12:30:23 GMT -5
Yeah I was curious why you specified “in the near future.” Because RLS 103 phase 1 for the acute anxiety in social anxiety disorder wraps up early next year. Receptor may be looking for a partner to take it through Phase 3 and ultimately commercialization (assuming Receptor is not planning on going solo). Hope this helps clear things up for you. |
|
